Market Overview 2022-2027:
The global point-of-care diagnostics market size reached US$ 41.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 69.4 Billion by 2027, exhibiting a growth rate (CAGR) of 9.06% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Point-of-care (PoC) diagnostics refer to the medical testing conducted to enable rapid analysis and obtain immediate results. PoC testing involves various portable instruments for glucose monitoring and infectious disease, cardiometabolic and urinalysis testing, among others. It aids in the early detection of critical illnesses, thus providing an enhanced patient-centric approach of healthcare. This kind of medical testing is widely utilized for supplying diagnostic facilities to remote locations where it is difficult to set up clinical laboratories. Owing to this, PoC testing essentials are integrated with medical vehicles, including helicopters, air ambulances, airplanes and spacecraft.
Global Point-of-Care Diagnostics Market Trends:
The growing prevalence of chronic diseases, which lead to increased morbidity and mortality rates, is one of the key factors driving the growth of the market. Furthermore, the increasing geriatric population across the globe, which is more prone to chronic illnesses, is also providing a thrust to the market. Moreover, infectious diseases such as Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), dengue fever, malaria and influenza require timely diagnosis and rapid screening, which is usually done through PoC diagnostic devices. Additionally, owing to the development of miniaturized devices and the integration with wireless technology, healthcare professionals can maintain electronic medical records (EMR) and provide more personalized intervention to individual patients. These records enable the direct transmission of test results from PoC devices to a specialist in the lab, thus minimizing the chances of discrepancies in the obtained test results. Moreover, the advent of home-testing cancer kits, which can actively monitor and analyze tumor cells, is further acting as a growth-inducing factor. Other factors, including enhanced research and development (R&D) to develop molecular diagnostic devices and the rising awareness for early detection of diseases, are projected to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global point-of-care diagnostics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, platform, prescription mode and end-user.
Breakup by Product Type:
- Blood-Glucose Monitoring Kit
- Cardio-Metabolic Monitoring Kit
- Pregnancy and Fertility Testing Kit
- Infectious Disease Testing Kit
- Cholesterol Test Strip
- Hematology Testing Kit
- Others
Breakup by Platform:
- Lateral Flow Assays
- Dipsticks
- Microfluidics
- Molecular Diagnostics
- Immunoassays
Breakup by Prescription Mode:
- Prescription-Based Testing
- OTC Testing
Breakup by End-User:
- Professional Diagnostic Centers
- Home Care
- Research Laboratories
- Others
Breakup by Region:
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Instrumentation Laboratory, Johnson & Johnson, Nova Biomedical Corporation, Pts Diagnostics, Qiagen, Siemens, Trinity Biotech, etc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2021 |
Historical Period |
2016-2021 |
Forecast Period |
2022-2027 |
Units |
US$ Billion |
Segment Coverage |
Product Type, Platform, Prescription Mode, End-User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Instrumentation Laboratory, Johnson & Johnson, Nova Biomedical Corporation, Pts Diagnostics, Qiagen, Siemens and Trinity Biotech |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |